Wednesday 13:00-13:45, Hall 10

Dr Philip Smith and Dr Sreedhar Subramanian present their real-world experience of switching to subcutaneous infliximab from IV infliximab which has been accepted for publication in the Journal of Crohn’s and Colitis. They also discuss the potential research questions associated with this new formulation including treating patients with perianal Crohn’s disease, treatment, dosing, and potential immunogenicity implications either using subcutaneous infliximab as monotherapy or with immunomodulators.  There will also be an opportunity to take questions and answers from the audience in this interactive symposium.

Dr. Philip Smith: Consultant Gastroenterologist, Royal Liverpool Hospital

Dr. Sreedhar Subramanian: Consultant Gastroenterologist, Cambridge University Hospital

Agenda:

  • Introduction – Dr Philip Smith and Dr Sreedhar Subramanian (1-2 minutes)
  • ‘Real world data: EFFICACY AND SAFETY OF ELECTIVE SWITCHING FROM INTRAVENOUS TO SUBCUTANEOUS INFLIXIMAB (CT-P13): A MULTI-CENTRE COHORT STUDY published in Journal of Crohn’s and Colitis – Dr Philip Smith (15-20 minutes)
  • ‘Subcutaneous infliximab – unanswered research questions – lessons from other anti-TNF therapies: perianal disease, immunomodulators and treatment escalation’ – Dr Sreedhar Subramanian (potentially interactive-polling) (15-20 minutes)